Brief: Fusen Pharmaceutical Company Sees HY Profit Attributable Increase By Not Less Than 40%
24/08/2020 13:57
Aug 24 (Reuters) - Fusen Pharmaceutical Company Ltd
1652.HK :
* SEES INCREASE IN HY PROFIT ATTRIBUTABLE BY NOT LESS THAN
40%
* EXPECTED INCREASE IN NET PROFIT MAINLY DUE TO INCREASE IN
SALES
OF SHUANGHUANGLIAN ORAL SOLUTIONS
Source text https://bit.ly/34FF9LB
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA